Protara Therapeutics(US:TARA) Seeking Alpha·2025-12-03 20:43Group 1 - The call is focused on the updated interim results from the ongoing Phase II open-label ADVANCED-2 trial of TARA-002, which targets patients with non-muscle invasive bladder cancer [2] - Justine O'Malley, Senior Vice President of Investor Relations and Corporate Affairs, is leading the update call [2] - The conference is being recorded, and participants are reminded to disconnect if they have objections [1] Group 2 - Forward-looking statements will be made during the call, representing the company's views as of the current date [3] - Actual results may differ from these forward-looking statements due to various factors, as outlined in the Risk Factors section of the company's most recent annual report [4] - The company disclaims any obligation to update these forward-looking statements except as required by law [4]